Nadine H.
- Country
- France
- Department
- Oncologie Medicale
Research Overview
- A Phase 3 Study of JNJ-78278343 and Docetaxel Versus Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
- A Phase 3 Study of MK-2870 Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced or Metastatic Urothelial Carcinoma
- Perioperative Durvalumab plus Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Global Open-Label Single-Arm Study
Data & Insights
Has run more than one trial at 270 of 501 partner sites.
Specializations
Urologic Oncology
The investigator specializes in treating various forms of urologic cancers, with particular focus on bladder cancer and prostate cancer management.
- Muscle-invasive bladder cancer treatment
- Non-muscle invasive bladder cancer therapy
- Advanced urothelial carcinoma
- Metastatic prostate cancer interventions
Expertise includes both localized and metastatic disease states, incorporating novel therapeutic approaches.
Kidney Cancer Treatment
Focuses on comprehensive treatment of renal cell carcinoma, including both early-stage and advanced disease management.
- Metastatic renal cell carcinoma therapy
- Post-surgical adjuvant treatment
- Advanced kidney cancer interventions
Implements integrated treatment strategies combining immunotherapy and targeted approaches.
Immunotherapy Applications
Specializes in immune checkpoint inhibitor therapy across multiple urologic cancers.
- Combination immunotherapy protocols
- Novel immunotherapy agents
- Maintenance therapy strategies
Develops treatment protocols utilizing various immunotherapeutic approaches in urologic oncology.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.